Arcutis Biotherapeutics, Inc. vs Pfizer, Inc. — Stock Comparison
Q·Score Breakdown
7
Bullish
Overall
6.5
Neutral
Quality
Health
Growth
Valuation
Sentiment
ARQT
Consensus analyst target of $34.75 is 49% above current price.
⚠ currently unprofitable (-4% margin).
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
Analyst Consensus
BUY
Target $34.75 (+48.8%)
8 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts
Fundamentals
ARQT
PFE
—
Trailing P/E
19.4×
19.4×
Forward P/E
9.4×
-4.3%
Profit Margin
12.4%
90.2%
Gross Margin
75.8%
-9.3%
ROE
8.9%
81.5%
Revenue Growth
-1.2%
—
Earnings Growth
—
1.77
Beta
0.39
—
Price / Book
—
$2.9B
Market Cap
$149.8B
$12 – $32
52-Week Range
$22 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →